Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection: Two-year follow-up data

Journal of Clinical Gastroenterology

Volumn 45, Issue 10, 2011, Pages 893-899

  Yoon, Eileen L ^a   Yim, Hyung Joon ^a   Lee, Hyun Jung ^a   Lee, Young Sun ^a   Kim, Jeong Han ^a   Jung, Eun Suk ^a   Kim, Ji Hoon ^a   Seo, Yeon Seok ^a   Yeon, Jong Eun ^a   Lee, Hong Sik ^a   Um, Soon Ho ^a   Byun, Kwan Soo ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

chronic hepatitis B; clevudine; entecavir; resistance; treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; CLEVUDINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MYOPATHY; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 80054123467     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31821f8bdf     Document Type: Article

References (40)

1. World Health Organization. Hepatitis B fact sheet [WHO Web site]. August 1, 2008, Available at: http://www.who.int/mediacentre/factsheets/fs204/en/. (Accessed December 20, 2010).
2. Palumbo E. New drugs for chronic hepatitis B: a review. Am J Ther. 2008;15:167-172.
3. Lim SG, Leung N, Hann HW, et al. Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2008;27:1282-1292.
4. Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis. B Hepatology 2007;45:1172-1178.
5. Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology. 2007;46:1041-1048.
6. Lee JS, Park ET, Kang SS, et al. Clevudine demonstrates potent antiviral activity in naive chronic hepatitis B patients. Intervirology. 2010;53:83-86.
7. Palumbo E. Entecavir for chronic hepatitis B: a review. Ther Drug Monit. 2008;30:1-4.
8. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-1010.
9. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011-1020.
10. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422-430.
11. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleosidenaive patients is rare through 5 years of therapy. Hepatology. 2009;49:1503-1514.
12. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283.
13. Shim JH, Suh DJ, Kim KM, et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology. 2009;50:1064-1071.
14. Lee CH, Kim SO, Byun KS, et al. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology. 2006;130:1144-1152.
15. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
16. Lee KS, Kim DJ. Management of chronic hepatitis B. Korean J Hepatol. 2007;13:447-488. (Korean).
17. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-242.
18. Han SH, Chang TT, Chao YC. Five years of continous entecavir for nucleoside-naive HBeAg+ chronic hepatitis B: results from study ETV-901 [abstract]. Hepatology. 2008;48:705A-706A.
19. Tenney DJ, Pokornowski KA, Rose RE. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients [abstract]. J Hepatol 2009;50:S10.
20. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133:1437-1444.
21. Liaw YF, Chang TT, Wu SS. Long-term histologic improvement with entecavir therapy in patients with chronic hepatitis B from Japaneses and worldwide development programs [abstract]. Gastroenterology. 2009;136:A798-A799.
22. Kim MH, Kim KA, Lee JS, et al. Efficacy of 48-week clevudine therapy for chronic hepatitis B. Korean J Hepatol. 2009;15:331-337. (Korean).
23. Ko SY, Kwon SY, Choe WH, et al. Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study. Antivir Ther. 2009;14:585-590.
24. Jang JH, Kim JW, Jeong SH, et al. Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. J Viral Hepat. 2011;18:84-90.
25. Kwon SY, Park YK, Ahn SH, et al. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol. 2010;84:4494-4503.
26. Lee HJ, Eun JR, Lee CH, et al. Long-term clevudine therapy in nucleos (t) ide-naive and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases. Korean J Hepatol. 2009;15:179-192. (Korean).
27. Balakrishna Pai S, Liu SH, Zhu YL, et al. Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methylbeta-L-arabinofuranosyl uracil. Antimicrob Agents Chemother. 1996;40:380-386.
28. Chu CK, Boudinot FD, Peek SF, et al. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antivir Ther. 1998;3:113-121.
29. Tak WY, Park SY, Jung MK, et al. Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients. Hepatol Res. 2009;39:944-947.
30. Seok JI, Lee DK, Lee CH, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology. 2009;49:2080-2086.
31. Kim BK, Oh J, Kwon SY, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol. 2009;51:829-834.
32. Tak WY, Park SY, Cho CM, et al. Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol. 2010;53:261-266.
33. Wang J, Eriksson S. Phosphorylation of the anti-hepatitis B nucleoside analog 1-(20-deoxy-20-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity. Antimicrob Agents Chemother. 1996;40:1555-1557.
34. Sun H, Mangner TJ, Collins JM, et al. Imaging DNA synthesis in vivo with 18F-FMAU and PET. J Nucl Med. 2005;46:292-296.
35. Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos (t) ide analog therapy for hepatitis B. J Hepatol. 2009;51:787-791.
36. Zhang XS, Jin R, Zhang SB, et al. Clinical features of adverse reactions associated with telbivudine. World J Gastroenterol. 2008;14:3549-3553.
37. Kim HJ, Park DI, Park JH, et al. Comparison between clevudine and entecavir treatment for antiviral-naive patients with chronic hepatitis B. Liver Int. 2010;30:834-840.
38. Division of AIDS table for grading the severity of adult and pediatric adverse events. [UC Davis Web site]. December 1, 2004. Available at: http://www.ucdmc.ucdavis.edu/clinicaltrials/documents/DAIDS-AE-GradingTable- FinalDec2004.pdf. (Accessed December 20, 2010).
39. Lee KS. Clevudine therapy in patients with chronic hepatitis B. Korean J Hepatol. 2009;15:119-121. (Korean).
40. Abbas Z, Jafri W, Raza S, et al. Hepatitis D: scenario in the Asia-Pacific region. World J Gastroenterol. 2010;16:554-562.